Surgery Partners, Inc. (SGRY)

NASDAQ: SGRY · USD

$23.2

-0.14 (-0.6%)· Recorded snapshot

Market cap	3B
Revenue (ttm)	3.4B
Net income (ttm)	-88.6M
EPS (ttm)	-$0.69
Shares out	129.7M
P/E (forward)	97.0x
Volume	2,696,724
Beta	1.91

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.4B
Net income (ttm): -88.6M
EPS (ttm): -$0.69
P/E (forward): 97.0x
Market cap: 3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E97

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE2.3

P25 n/aP50 n/aP75 n/a

ROIC5.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SGRY indicators

Market & fundamental data

Available fields

245

Groups with data

Currency

USD

Showing 245 of 245 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001638833
Company name	Surgery Partners, Inc.
Country	United States
Country code	US
CUSIP number	86881A100
Earnings date	2026-11-09
Earnings time	bmo
Employees	16,000
Employees change	1,000
Employees growth	6.67%
Enterprise value	$6.9B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2004
In index	RUSSELL2000
Industry	Medical Care Facilities
IPO date	2015-10-01
Is primary listing	Yes
Is SPAC	No
ISIN number	US86881A1007
Last 10-K release date	2026-03-02
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$3B
Market cap category	Mid-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$23.22
Price currency	USD
Sector	Healthcare
SIC code	8062
Stock price date	2026-10-28
Symbol	SGRY
U.S. state	Tennessee
Website	https://www.surgerypartners.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	72.56x
Earnings yield	-2.98%
EV/EBIT	14.62x
EV/EBITDA	10.61x
EV/FCF	36.57x
EV/Sales	2.04x
FCF / EV yield	2.73%
FCF yield	6.23%
Forward EV/Sales	2.38x
Forward P/E	96.95x
Forward P/S	1.04x
Industry forward P/E	14.81x
Industry P/E	18.21x
P/(FCF - SBC) ratio	16.95x
P/(OCF - SBC) ratio	12.14x
P/B ratio	1.81x
P/FCF ratio	16.05x
P/OCF ratio	11.67x
P/S ratio	0.89x
Price/EBITDA ratio	4.66x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	13.94%
EBITDA margin	19.2%
Effective tax rate	20.02%
FCF margin	5.57%
Gross margin	22.51%
Operating margin	13.94%
Pretax margin	3.04%
Profit margin	-2.63%
Profit per employee	$-5,538
Revenue per employee	$210,394
ROA	3.66%
ROA (5Y)	3.71%
ROCE	6.28%
ROE	2.32%
ROE (5Y)	2.78%
ROIC	5.12%
ROIC (5Y)	4.75%
SBC / revenue	0.3%
Tax / revenue	0.61%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
FCF growth	7.02%
FCF growth (Q)	-35.23%
FCF growth 3Y	36.72%
FCF growth 5Y	38.14%
Gross profit growth	-1.39%
Gross profit growth (Q)	-2.76%
Gross profit growth 3Y	7.88%
Gross profit growth 5Y	9.96%
Net income growth years	1
OCF growth	-2.24%
OCF growth (Q)	-27.06%
OCF growth (QoQ)	406.84%
OCF growth 10Y	7.3%
OCF growth 3Y	16.42%
OCF growth 5Y	23.92%
Operating income growth	-3.1%
Operating income growth (Q)	-3.96%
Operating income growth 3Y	6.37%
Operating income growth 5Y	11.41%
Revenue growth	3.99%
Revenue growth (Q)	2.75%
Revenue growth (QoQ)	4.69%
Revenue growth 10Y	12.48%
Revenue growth 3Y	8.15%
Revenue growth 5Y	9.9%
Revenue growth quarters	24
Revenue growth years	12

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-70.4M
Depreciation and amortization	$177.2M
EBIT	$469.2M
EBITDA	$646.4M
EPS	$-0.69
FCF per share	$1.45
Financing cash flow	$-85.9M
Free cash flow	$187.6M
Free cash flow minus SBC	$177.6M
Gross profit	$757.9M
Income taxes	$20.5M
Investing cash flow	$-205.5M
Net borrowing	$119.8M
Net cash flow	$-33.4M
Net income	$-88.6M
Operating cash flow minus SBC	$248M
Operating income	$469.2M
Revenue	$3.4B
Stock-based compensation	$10M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.83
Book value per share	$12.88
Debt / EBITDA	5.51
Debt / equity	1.17
Debt / FCF	21.68
Goodwill	$5.2B
Interest coverage	1.6
Long-term assets	$6.9B
Long-term liabilities	$4B
Net cash (debt)	$-3.9B
Net cash / market cap	-127.89%
Net debt / EBITDA	5.96
Net debt / equity	1.11
Net debt / FCF	20.52
Piotroski F-Score	5
Property, plant and equipment	$1.4B
Shareholders' equity	$3.5B
Tangible book value	$-3.6B
Tangible book value per share	$-27.54
Total assets	$8B
Total cash	$216.7M
Total debt	$4.1B
Total liabilities	$4.6B
WACC	9.59%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.42
Current assets	$1.1B
Current liabilities	$578.5M
Current ratio	1.95
Inventory turnover	28.03
Net working capital	$474.3M
Quick ratio	1.44
Working capital	$547.5M
Working capital turnover	6.24

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.28%
Dividend yield	0%
Shareholder yield	-1.28%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	39.29%
10Y return CAGR	3.37%
10Y total return	39.29%
150-day SMA	$14.61
1D price change	-0.6%
1M price change	61.25%
1M total return	61.25%
1W price change	50.78%
1W total return	50.78%
1Y price change	1.4%
1Y return CAGR	1.4%
1Y total return	1.4%
20-day SMA	$15.73
200-day SMA	$14.55
3M price change	53.07%
3M total return	53.07%
3Y price change	3.57%
3Y return CAGR	1.18%
3Y total return	3.57%
50-day SMA	$14.75
50-day SMA vs 200-day SMA	50over200
52-week high	$23.44
52-week high date	2025-10-29
52-week low	$11.41
52-week low date	2026-03-30
5Y price change	-42.05%
5Y return CAGR	-10.34%
5Y total return	-42.05%
6M price change	59.7%
6M total return	59.7%
All-time high	$69.58
All-time high date	2021-06-25
All-time low	$4.00
All-time low date	2020-03-18
Average true range (ATR)	$0.99
Average volume	5.2M
Beta (1Y)	1.17
Beta (2Y)	1.17
Beta (5Y)	1.91
Change from 52-week high	-0.94%
Change from 52-week low	103.51%
Change from all-time high	-66.63%
Change from all-time low	480.5%
Change from open	-0.26%
Day's gap	-0.34%
Dollar volume	$62.6M
High price	$23.36
Low price	$23.20
Monthly RSI	54.71
Open price	$23.28
Position in 52-week range	12.5%
Premarket change	-0.34%
Premarket close	$23.36
Premarket price	$23.28
Previous close	$23.36
Price vs 150-day SMA	58.91%
Price vs 20-day SMA	47.61%
Price vs 200-day SMA	59.57%
Price vs 50-day SMA	57.4%
Relative volume	0.53
RSI	86.27
Sharpe ratio	0.29
Sharpe ratio (3Y)	0.16
Sharpe ratio (5Y)	0.01
Sortino ratio	0.59
Sortino ratio (3Y)	0.38
Sortino ratio (5Y)	0.12
Volume	2.7M
Weekly RSI	75.32
YTD price change	50.29%
YTD total return	50.29%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	58.8M
Float percentage	45.29%
Shares change (QoQ)	0.36%
Shares change (YoY)	1.28%
Shares held by insiders	1.82%
Shares held by institutions	74.51%
Shares outstanding	129.7M
Short % of float	24.39%
Short % of shares	11.05%
Short ratio	5.7 days

Deeper analysis on SGRY

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SGRY report

Is a complete SGRY research report available?

No complete published report is available for Surgery Partners, Inc. (SGRY) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Surgery Partners, Inc. (SGRY)

Price

Financial snapshot

Fair-value bridge

Latest news · SGRY

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SGRY indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SGRY

Frequently asked questions